Initiative to Minimize Disparities in Postoperative Prostate Cancer Care

• Status: Not yet recruiting
• Trial end date: 2020-03-01
• Target enrollment: 30
• Participant gender: Male

Summary

Einstein Healthcare Network in North Philadelphia serves a predominantly underserved medical community. The investigators routinely see patients who cannot afford PDE-5 inhibitors and absorbent pads after prostate surgery, which help with sexual rehabilitation after surgery and reduced quality of life secondary to urinary incontinence after surgery, respectively. The goal of our study is to provide PDE-5 inhibitors and absorbent pads to patients who would be unable to afford them. We hypothesize that providing PDE-5 inhibitor (Tadalafil 4mg taken every other day for 6 months) and absorbent pads for 6 months will result in improved sexual health and management of urinary incontinence after radical prostatectomy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Albert Einstein Healthcare Network
• Treatments: Tadalafil

Criteria

Inclusion Criteria:

1. History of prostate cancer

2. Scheduled for radical prostatectomy during a designated academic year (depends on SEED Grant Application approval)

3. Reside within Health Enterprise Zone (HEZ) of North Broad Street - Zip codes included within the HEZ are 19120, 19130, 19132, 19138, 19140, and 19144.

4. Median annual household income < $40,000

5. Patient feels that they would struggle to afford absorbent pads and Tadalafil based on their annual income

6. Patient must have no history of stress urinary incontinence

7. Patient must have adequate erectile function (SHIM score of 17 or higher)

9) Patient must have adequate erectile function without the help of PDE-5 inhibitors (such as Tadalafil)

Exclusion Criteria:

1. Patient's who do not meet the inclusion criteria above

2. Patients who meet all inclusion criteria above, but are not candidates to take Tadalafil secondary to cardiovascular comorbidities